Amgen reported a mixed Q1 performance with a 4% revenue decline, but management maintained confidence by reaffirming full-year guidance and increasing share repurchase commitments. The optimism around pipeline advancements and strategic acquisitions may offset concerns over short-term revenue pressures, likely supporting the stock in the near term.

[1]